177Lu-PSMA-617 is in clinical development for patients with metastatic castrationresistant prostate cancer (mCRPC) who have been previously treated with androgen receptor-directed therapy (ARDT) and a taxane-based chemotherapy. Prostate cancer is a cancer of the prostate gland and mCRPC is when the cancer has spread to parts of the body other than the prostate, and it is able to grow and spread even though drugs or other treatments to lower the amount of male sex hormones are being used to manage the cancer. The symptoms of prostate cancer may vary depending on the stage but can include pain, tiredness, and problems emptying the bladder and the bowels. Treatment options for mCRPC are currently limited in patients that have progressed following treatment with ARDT and a taxane-based chemotherapy.
177Lu-PSMA-617 delivered via intravenous infusion. It works by releasing an energetic beta particle to precisely deliver cell-killing radiation to the site of disease to kill cancer cells. Earlier studies indicate that 177Lu-PSMA-617 may demonstrate clinical benefit in patients with mCRPC in the third-line setting, where patients have no clear standard of care, having exhausted all key treatment options. If licensed, 177LuPSMA-617 will provide a treatment option for patients in this setting.